IPOs

From day 1 Gossamer has always been a biotech in a hurry. And they?re not about to let a little thing like a government shutdown stymy their plans for an IPO.
As the partial US government shutdown continues to paralyze the SEC, Gossamer Bio has elected… […]

Is there enough enthusiasm among biotech investors to push through a $115 million-plus IPO on the latest biotech staking out their claim with a new-and-improved BCMA CAR-T therapy?
Poseida Therapeutics is aiming to find that out in the very near future… […]